Crescent Biopharma, Inc. filed a prospectus supplement on July 30, 2026, updating its securities registration to reflect the company's most recent quarterly financial results for the period ended June 30, 2026. The update covers the resale of approximately 19.6 million ordinary shares by selling securityholders. As of July 29, 2026, the company's ordinary shares were trading at $14.77 per share on the Nasdaq Capital Market under the ticker CBIO.

Key Points

  • NASDAQ: CBIO
  • Prospectus supplement filed to update securities offering with June 30, 2026 quarterly results
  • Approximately 19.6 million ordinary shares eligible for resale by selling securityholders; 37.1 million shares outstanding as of July 27, 2026
  • Stock price at $14.77 per share on July 29, 2026

Updated Registration Covers Significant Share Resale Authorization

The prospectus supplement updates the company's existing registration statement on Form S-1, detailing the resale of up to 19,580,843 ordinary shares by identified selling securityholders. The disclosed share count comprises 13,534,837 outstanding ordinary shares issued through a private placement, 131,434 shares issuable upon exercise of pre-funded warrants, and additional holdings by Fairmount Healthcare Fund II L.P., including 1,387,866 outstanding shares, 1,636,706 shares from warrant exercises, and 2,890,000 shares convertible from Series A non-voting convertible preferred shares. This registration supersedes prior prospectus versions and incorporates updated financial and operational disclosures from the company's quarterly filing.

Quarterly Financial Update Incorporated into Public Offering Documents

The filing states that the prospectus supplement updates and amends the original prospectus dated March 3, 2026, by incorporating information from the company's quarterly report for the period ended June 30, 2026. The disclosure requires that investors read the supplement in conjunction with the base prospectus, as the new information updates or supersedes prior disclosures. The company operates as a Cayman Islands incorporation with its principal executive offices in Waltham, Massachusetts, and maintains registration with the Securities and Exchange Commission under file number 001-36177.

Company Classification and Regulatory Status

Crescent Biopharma is classified as both a smaller reporting company and a non-accelerated filer under SEC regulations. As of July 27, 2026, the company had 37,143,940 ordinary shares outstanding. The company confirmed its compliance with all required quarterly reporting obligations and has not elected to use extended transition periods for new accounting standards. The filing confirms that the company is not a shell company and has maintained required interactive data submissions to the SEC.